Buy Vasaprostan

Vasaprostan is prescribed in case of:

 

• Chronic obliterating arterial diseases of stages III and IV (according to Fontaine classification) in patients who cannot undergo revascularization or after unsuccessful revascularization.

 

Intravenous use in the treatment of chronic obliterating arterial diseases of stage IV is not recommended.

 

According to numerous reviews, the drug is effective against lower limb cramps, limping, trophic ulcers associated with arterial ischemia or diabetic retinopathy. It has helped many people to avoid serious complications such as amputation and disability.

 

Vasaprostan has another specific area of application - treatment of erectile dysfunction.

1 ampoule of Vasaprostan contains:

 

Active ingredient: alprostadil (clathrate complex with alphadex 1:1) 20.0 µg;

 

Auxiliaries: Alfadex 646.7 µg, anhydrous lactose 47.5 mg.

 

Alprostadil = PGE1 (prostaglandin E1), INN.
Alfadex = alpha-cyclodextrin (alpha-zd), INN.

Inject only intravenously or intraarterially.

 

 

Intraarterial injection

 

Dissolve the contents of 1 ampoule of Vasaprostan lyophilizate (corresponds to 20 µg alprostadil) in 50 ml of physiological solution.

 

In the absence of other regulations, half of the contents of the Vasaprostan ampoule (corresponds to 10 µg alprostadil) is injected for 60-120 min when using a device for infusion. If necessary, especially in the presence of necrosis, the dose can be increased up to 20 µg alprostadil (1 ampoule) under strict tolerability control. This dosage is usually used for a single daily infusion.

 

If intraarterial infusion is carried out through an infusion catheter, depending on the tolerance and severity of the disease, a dose of 0.1 - 0.6 ng/kg/min is recommended with 12 hours of administration (corresponds to 0.25 - 1.5 ampoules of Vasaprostan).

 

 

Intravenous infusion

 

Dissolve the contents of 2 ampoules of Vasaprostan lyophilizate (corresponds to 40 µg alprostadil) in 50-250 ml of physiological solution and inject the resulting solution intravenously for 2 hours 2 times a day or 3 ampoules (60 µg alprostadil) for 3 hours 1 time a day.

 

In patients with impaired renal function (renal failure at creatinine level more than 1.5 mg/dL) intravenous injection starts at 20 µg for 2 hours. If necessary, after 2-3 days a single dose is increased to 40-60 micrograms.

 

For patients with renal and heart failure, the maximum volume of injected fluid is 50-100 ml/day. Course of treatment - 4 weeks.

 

The duration of treatment - 14 days on average, in case of a positive effect the treatment can be continued for another 7-14 days. If there is no positive effect within 2 weeks from the start of treatment, further use of the drug should be stopped.

The solution must be prepared immediately before infusion. Lyophilizate is dissolved immediately after adding the physiological solution.

At the beginning, the solution may turn out to be milky muddy. This effect is created by air bubbles and is not important.

After a short time, the solution becomes transparent.

The solution prepared more than 12 hours ago should not be used.

Symptoms:

Decreased BP, increased NHS. Vasovagal reactions are possible with pale skin, increased sweating, nausea and vomiting, which may be accompanied by myocardial ischemia and symptoms of heart failure, and pain, swelling and redness of the tissue at the infusion site.

 

Treatment:

The dose should be reduced or the infusion stopped. If there is a marked decrease in BP, the patient should lift his legs lying down. If symptoms persist, it is necessary to use sympathomimetics.

 

• Hypersensitivity to alprostadil or other components of the drug;

 

• Chronic heart failure of functional class III-IV according to NYHA;

 

• Hemodynamically significant heart rhythm disorders;

 

• Acute course of coronary heart disease, suffered in the last six months of myocardial infarction;

 

• Mitral and/or aortic stenosis and/or failure;

 

• Acute pulmonary oedema or the presence of pulmonary oedema in the history of patients with heart failure;

 

• Severe chronic obstructive pulmonary disease or pulmonary venoclusionic disease;

 

• Infiltrative pulmonary disease;

 

• Diseases with an increased risk of bleeding (gastric and/or duodenal ulcer);

 

• Associated therapy with vasodilators or anticoagulants;

 

• Disruption of cerebral blood flow during the last 6 months;

 

• Severe arterial hypotension;

 

• Disorders of renal function (oliguria);

 

• Acute hepatic failure (increased activity of aspartatamin transferase, alanine transferase or gamma-glutamyl transferase) or severe hepatic failure, including in anamnesis;

 

• General contraindications for infusion therapy (e.g. chronic heart failure, edema and pulmonary or brain hyperhydration);

 

• Pregnancy and breastfeeding period;

 

• Under 18 years of age (efficacy and safety not determined).

 

 

Careful:

 

• Arterial hypotension.

 

• Chronic heart failure of NYHA functional class I-II (special attention should be paid to control the load of the carrier solution volume).

 

• Patients with diabetes mellitus type 1, especially in case of extensive vascular lesions (elderly patients).

 

• Patients on hemodialysis (treatment with the drug should be performed in the postdialysis period).

Nervous system: headache, convulsive syndrome, dizziness, increased fatigue, a feeling of malaise, disturbance of sensitivity of the skin and mucous membranes.

 

Cardiovascular system: reduced BP, chest pain, heart rhythm disorders, AV block.

 

Digestive system: a sense of discomfort in the epigastric region, dyspeptic phenomena - diarrhea, nausea, vomiting.

 

Musculoskeletal system: hyperostosis of long tubular bones (in treatment for more than 4 weeks).

 

Local reactions: pain, swelling, erythema, sensitivity disorder, phlebitis (proximal to the place of administration).

 

Laboratory indicators: leukocytosis, leukocytopenia, increase in C-reactive protein titre, increase in transaminase level.

 

Other: increased sweating, hyperthermia, swelling of the limb, infusion of the vein.

 

Rarely: joint pain, confusion, central genesis convulsions, fever, chills, bradypnoea, arthralgia, psychosis, renal failure, anuria. Several cases of pulmonary edema and acute left ventricular failure have been reported.

 

Very rarely (up to 1% of cases): shock, acute heart failure, hyperbilirubinemia, bleeding, drowsiness, bradypnoea, reduced respiratory function, tachypnoea, anuria, renal impairment, hypoglycemia, ventricular fibrillation, AV blockade II degree, supraventricular arrhythmia, neck muscle tension, increased irritability, hypothermia, hypercapnia, hyperemia of the skin, hematuria, peritoneal symptoms, tachyfilaxia, hyperkalemia, thrombocytopenia, anemia.

 

Allergic reactions: skin rash, itching.

 

Side effects associated with the application of the drug or the procedure of catheterization itself, disappear after a dose reduction or cessation of infusion. 

 

It should be taken into account that the drug affects the speed of reaction, so it is better not to drive and not to do work that requires a quick reaction. 

According to expert reviews, alprostadil cannot be used in conjunction with erection enhancers. 

 

It should also be taken into account that the active ingredient enhances the effect of antihypertensive drugs, as well as vasodilators, antiaggregants, anticoagulants, thrombolitics, etc. 

 

On the other hand, sympathomimetics reduce the effectiveness of alprostadil. Therefore, before therapy, it is better to give up using the above medications in advance. 

 

Avoid alcoholic drinks when you use "Vasaprostan".

 

 

Vasaprostan has another very specific area of application - treatment of erectile dysfunction.

 

In case of intracavernous (in cavernous bodies of the penis) method of administration, the drug blocks alpha-1-adrenoro receptors that dot the tissues of the penis, relaxes smooth muscles of cavernous bodies, intensifies blood flow and improves blood circulation in capillaries.

 

The selection of the dose should be done under the supervision of a physician, under control of the cardiovascular system and the duration of erections.

 

Usually, Vasaprostan is used in doses from 1 µg to 40 µg. Intracavernous injection should be administered at intervals of 5 to 10 seconds.  

 

The patient should inform the doctor of all cases of an erection lasting more than 1 hour during treatment.

 

During treatment, an adequate contraceptive method should be used by a female partner of childbearing age.

At temperatures not exceeding 25 °C.

Keep out of the reach of children.

 

Shelf life: 4 years.

You can buy Vasaprostan from our website absolutely legally.

Delivery is carried out to all countries in the world, which do not have an official ban on receiving and sending mail (mainly island countries).

We guarantee that you will receive your parcel with Vasaprostan without any problems at customs (we have our own delivery channels to countries with strict customs).

We guarantee a refund if your package has not been delivered to you for any reason, according to PayPal protection policy.

Due to Quarantine, delivery time may increase slightly, but still delivery remains within reasonable limits and does not exceed the delivery time during Christmas sales.

There is no prescription required!

You can legally buy Vasaprostan on our website without prescription!